典型文献
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
文献摘要：
Dear Editor,
To May 2022,the COVID-19 pandemic has claimed more than 6.28 million lives,with more than 524 million confirmed cases worldwide.The recent emergence of highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has triggered another major surge in both confirmed cases and deaths.1 Ten COVID-19 vaccines have been approved by the World Health Organization(WHO)for emergency use,including the two mRNA vaccines,BNT162b2 and mRNA-1273,and two Chinese inactivated vaccines,CoronaVac and BBIBP-CorV.How-ever,the rapid waning of vaccine-induced virus-neutralizing antibody titers and the continuous emergence of variants of concern(VOCs),including Alpha,Beta,Delta and Omicron,have created unprecedented challenges in the eradication of COVID-19 pandemic.2-4
文献关键词：
中图分类号：
作者姓名：
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin
作者机构：
Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
文献出处：
引用格式：
[1]Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-.Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults)[J].细胞研究（英文版）,2022(08):777-780
A类：
B类：
Safety,superior,immunogenicity,heterologous,boosting,RBD,SARS,CoV,Chinese,adults,Dear,Editor,
To,May,pandemic,has,claimed,more,than,million,lives,confirmed,cases,worldwide,recent,emergence,highly,transmissible,Omicron,severe,acute,respiratory,syndrome,coronavirus,triggered,another,major,surge,both,deaths,Ten,vaccines,have,been,approved,by,World,Health,Organization,WHO,emergency,use,including,two,BNT162b2,inactivated,CoronaVac,BBIBP,CorV,How,rapid,waning,induced,neutralizing,antibody,titers,continuous,variants,concern,VOCs,Alpha,Beta,Delta,created,unprecedented,challenges,eradication
AB值：
0.696184
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
